Evidence map›Paper›PMID 34361072›Full record

ReviewInternational journal of molecular sciences2021

Failure to Guard: Mitochondrial Protein Quality Control in Cancer.

Joseph E Friedlander, Ning Shen, Aozhuo Zeng, Sovannarith Korm, Hui Feng

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Joseph E FriedlanderDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
Ning ShenDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
Aozhuo ZengDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
Sovannarith KormDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.ORCID 0000-0003-2211-2946
Hui FengDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.ORCID 0000-0003-1318-821X
Boston University · US

Funding

Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3M
RESEARCH TRAINING IN BLOOD DISEASES AND RESOURCEST32HL007501 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LERNER, ADAM, STEINBERG, MARTIN H. · 1985 to 2018
$5.4M
The Role of DLST in LeukemogenesisR01CA215059 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FENG, HUI · 2018 to 2022
$2.0M
The Role of DLST in LeukemogenesisR56CA215059 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FENG, HUI · 2017 to 2017
$376k
American Cancer Society RSG-17-204-01-TBGNational Science Foundation 1911253NCATS NIH HHS UL1 TR001430NCI NIH HHS CA215059NCI NIH HHS R01 CA215059NCI NIH HHS R56 CA215059NHLBI NIH HHS T32 HL007501NIH HHS 1UL1TR001430NIH HHS T32HL007501
6 · The paper itself

Abstract

Mitochondria are energetic and dynamic organelles with a crucial role in bioenergetics, metabolism, and signaling. Mitochondrial proteins, encoded by both nuclear and mitochondrial DNA, must be properly regulated to ensure proteostasis. Mitochondrial protein quality control (MPQC) serves as a critical surveillance system, employing different pathways and regulators as cellular guardians to ensure mitochondrial protein quality and quantity. In this review, we describe key pathways and players in MPQC, such as mitochondrial protein translocation-associated degradation, mitochondrial stress responses, chaperones, and proteases, and how they work together to safeguard mitochondrial health and integrity. Deregulated MPQC leads to proteotoxicity and dysfunctional mitochondria, which contributes to numerous human diseases, including cancer. We discuss how alterations in MPQC components are linked to tumorigenesis, whether they act as drivers, suppressors, or both. Finally, we summarize recent advances that seek to target these alterations for the development of anti-cancer drugs.

Indexed as

MitophagyProteostasisAnimalsHumansMitochondriaMitochondrial ProteinsNeoplasmsMitochondrial ProteinscancerchaperonemitochondriaMPQConcogeneproteaseproteostasistherapeutic targetingtumorigenesistumor suppressor

Identifiers

PMID34361072
PMCPMC8348654
OpenAlexW3188686710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.